IKT-001 in adults with pulmonary arterial hypertension

Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing IKT-001 plus background PAH therapy with Placebo plus background PAH therapy (2 arms). Primary endpoints: Part A: Change from baseline in pulmonary vascular resistance at Week 24 and Part B: Change from baseline in 6-minute walk distance at Week 24. Planned start Jul 2026; status: not yet recruiting.